BrandWikiReturn

Thermo Fisher Scientific

WorldBrand briefing

AI supplement

Original synthesis to sit alongside the encyclopedia article below. Not part of Wikipedia; verify facts on Wikipedia when precision matters.

Thermo Fisher Scientific is a leading global scientific instruments, reagents and services company headquartered in Waltham, Massachusetts, USA. It provides products and solutions for life sciences, analytical laboratories, clinical diagnostics and other fields, with the mission of helping customers make the world healthier, cleaner and safer.

Key moments

  • 1902Fisher Scientific founded by Chester G. Fisher in western Pennsylvania
  • 1956Thermo Electron established by Dr. George Hasopoulos at MIT
  • 2006Merger of Thermo Electron and Fisher Scientific to form Thermo Fisher Scientific
  • 2014Completed acquisition of Life Technologies Corporation
  • 2015Acquired Alfa Aesar and established its clinical diagnostics business unit

Thermo Fisher is a dominant player in the global scientific tools market, with several key competitive strengths:

  • Product portfolio breadth: Offers over 600,000 products spanning laboratory equipment, reagents, consumables and specialized services, covering nearly every segment of scientific research and industrial testing.
  • Acquisition-driven growth: Has a history of strategic acquisitions to expand its market reach and product lines, such as the purchase of Life Technologies which boosted its genomics and life science capabilities.
  • Global scale: Employs over 125,000 people worldwide, operates in nearly 100 countries, and has established a robust distribution and customer support network.

Its main competitors include:

  1. Danaher Corporation: A rival industrial science and diagnostics firm with a similar acquisition-focused growth strategy
  2. Agilent Technologies: Specializes in analytical instruments and life sciences research tools
  3. Sartorius AG: Focuses on bioprocessing and laboratory equipment for life sciences
  • Leading global scientific instruments and services provider with ~$44.9B annual revenue (2022)
  • Broad product ecosystem covering research, clinical diagnostics and biomanufacturing
  • Strong brand recognition in academic and industrial scientific communities

Thermo Fisher Scientific stands as one of the most powerful and trusted brands in the global life sciences and analytical instrumentation industry, with a brand identity built on reliability, innovation and customer-centric problem solving. Aligned with its mission to help customers make the world healthier, cleaner and safer, the brand has cultivated strong credibility across a diverse range of scientific and industrial stakeholders, from academic research labs to large pharmaceutical developers and clinical diagnostic providers. Its consistent focus on solving complex scientific challenges has positioned it as a preferred partner for organizations working at the cutting edge of life science and environmental research.

The brand’s strength is significantly reinforced by its decades-long strategy of strategic acquisitions, which have expanded its product portfolio and integrated well-established niche brands into its broader ecosystem. With over 600,000 products covering nearly every segment of scientific research and industrial testing, Thermo Fisher creates strong brand loyalty by meeting the full scope of customer workflow needs, reducing customer churn and increasing lifetime value. This breadth of offering also creates a significant competitive moat that strengthens the brand’s position relative to its peers.

In recent years, Thermo Fisher’s brand profile has received additional boosts from its central role in global public health initiatives, including pandemic response and advanced biotech development. This visibility has enhanced its reputation beyond the core scientific community, increasing overall brand recognition while reinforcing its core value proposition of enabling impactful scientific progress.

Brand leadership

Score: 92/100

Thermo Fisher holds a dominant leading position in the global scientific tools and diagnostics market, outranking key competitors in overall market share and brand recognition among research and clinical professionals. Its consistent investment in research and development and strategic brand positioning has cemented its status as the go-to brand for high-quality, innovative scientific solutions.

Customer interaction

Score: 88/100

The brand maintains deep, long-term interactions with a diverse global customer base that includes academic institutions, pharmaceutical companies, clinical laboratories and environmental testing agencies. It provides localized customer support and tailored workflow solutions, fostering high levels of customer satisfaction and repeat engagement across all core market segments.

Brand momentum

Score: 85/100

Fueled by steady strategic acquisition activity and growing global demand for life science research tools and clinical diagnostics, Thermo Fisher’s brand momentum remains consistently strong. It has expanded its footprint in high-growth areas such as genomics, cell therapy and bioprocessing, capturing increased brand attention and market share in fast-growing emerging biotech sectors.

Brand stability

Score: 90/100

Backed by a strong financial foundation and decades of operation in the scientific industry, Thermo Fisher demonstrates exceptionally high brand stability. It has consistently weathered economic downturns and market fluctuations, maintaining its reputation for product reliability and business continuity even during global supply chain disruptions and major public health crises.

Brand heritage

Score: 75/100

While the combined Thermo Fisher Scientific brand was formally established through the merger of Thermo Electron and Fisher Scientific in 2006, its predecessor entities collectively boast more than a century of history serving the scientific industry. This legacy gives the modern brand solid inherited trust, even as the unified brand itself is less than two decades old.

Industry profile

Score: 94/100

Thermo Fisher is one of the most visible and respected brands in the global scientific tools sector, widely recognized as an industry trendsetter whose product innovations and strategic moves shape overall market development. It maintains high profile across industry conferences, peer-reviewed research publications and large-scale collaborative research initiatives, further elevating its standing within the industry.

Global brand penetration

Score: 89/100

Thermo Fisher operates in nearly 100 countries worldwide, with a robust localized distribution and customer support network spanning North America, Europe, Asia-Pacific and emerging market regions. It has tailored its offerings to meet regional regulatory and customer needs, achieving high brand penetration in both developed and developing scientific communities, with only minor gaps in smaller, less developed regional markets.

AI-driven analysis can support structured reasoning around Thermo Fisher Scientific's brand value, helping frame the key drivers that contribute to its overall brand equity. All derived figures in this supplementary analysis are illustrative and not independently audited. For official, audited brand value assessments and reports for Thermo Fisher Scientific, please contact World Brand Lab directly.

Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013),[2] Alfa Aesar (2015),[3] Affymetrix (2016),[4] FEI Company (2016),[5] BD Advanced Bioprocessing (2018),[6] and PPD (2021).[7]

It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.[8]

History

Predecessors and merger

Thermo Electron was co-founded in 1956 by George N. Hatsopoulos and Peter M Nomikos. Hatsopoulos received a PhD from MIT in mechanical engineering and Nomikos was a Harvard Business School graduate.[9] The company focused on providing analytical and laboratory products, and had revenues of over $2 billion in 2004.[10]

Fisher Scientific was founded in 1902 by Chester G. Fisher from Pittsburgh.[11][12] It focused on providing laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety, and education.[13]

On May 8, 2006, Thermo Electron and Fisher Scientific announced that they would merge in a tax-free, stock-for-stock exchange; the merged company was named Thermo Fisher Scientific, and had about 30,000 employees, and reported US$9 billion in combined revenue.[14] On November 9, 2006, the companies announced that the merger had been completed.[15] However, the Federal Trade Commission ruled that this acquisition was anti-competitive regarding centrifugal evaporators, requiring Fisher to divest Genevac.[16] In April 2007, Genevac was sold to Riverlake Partners LLC[17] and the merger closed with FTC approval.[18]

The company's products are sold under the brand names of Thermo Scientific, Fisher Scientific, and several other recognized brand names (e.g. Applied Biosystems, Invitrogen, Patheon, PPD, and Nalgene). According to company figures, as of 2007, 46% of its sales were in life sciences, 20% in healthcare, and 34% in industrial/environmental and safety.[13]

Acquisition history

In 1990, Thermo Fisher Scientific (then known as Thermo Instrument Systems) acquired mass spectrometer manufacturer Finnigan Instrument Corporation.[19]

In 2003, the company (then Fisher Scientific International) acquired Perbio Science, a transaction that included brands such as Pierce Biotechnology, HyClone and Endogen.[20] In April 2006, BioImage was acquired by Thermo Fisher Scientific.[21] The merger was complete in November 2006, and technology transfer to a US site was completed during 2007 and 2008.[22][23] BioImage was established in 1993 as a drug discovery research unit led by Ole Thastrup within Novo Nordisk, from which it spun out of in 1999. It had specialized in developing and selling proprietary bioassays to biopharmaceutical companies and research institutions. It made broad patents covering Enhanced GFP (EGFP), GFP-based biosensors and any genetically encoded protein fusion to a luminophore, with subsequent monitoring of the protein's translocation within a cell as the primary readout for drug discovery assays.[24]

In December 2010, Thermo Fisher Scientific announced its acquisition of Dionex for $2.1 billion.[25]

In May 2011, Thermo Fisher Scientific Inc. bought Phadia to expand into the testing of allergies and autoimmune diseases for €2.47 billion ($3.5 billion) in cash.[26]

In April 2013, after a competitive bidding with Hoffmann-La Roche,[27] Thermo Fisher acquired Life Technologies Corporation for US$13.6 billion in a deal, adding further service lines related to advanced DNA sequencing and genetic testing.[28] Life Technologies was originally formed in 2008 through a $6.7B merger of Invitrogen, a cell therapy, and Applied Biosystems.[29] The company also acquired GIBCO (Grand Island Biological Company) as part of the Life Technologies acquisition.[30]

In February 2015, the company announced it would acquire Advanced Scientifics for $300 million in a cash-deal. ASI designs manufactures, and delivers technologies used in bioprocessing.[31] In June 2015, the company announced its intention to acquire Alfa Aesar, a global manufacturer of research chemicals for $405 million[32] from Johnson Matthey, and the acquisition was completed at the end of September[33]

In January 2016, the company announced it would acquire Affymetrix for $1.3 billion.[34] On May 27, 2016, the company announced it would acquire FEI Company for $4.2 billion, a manufacturer of electron microscopes.[35] This acquisition is anticipated to close in early 2017 and will contribute to the growth of Thermo's Analytical Instruments business group.[36] In November the company announced it would acquire MTI-GlobalStem, a previously privately held company that develops reagents for cell transfection, neurobiology and stem cell research.[37]

In February 2017, the company acquired Finesse Solutions, Inc., developer of scalable control automation systems and software for bioproduction after receiving early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.[38] The transaction was completed a day later.[39] In March, the company announced it would acquire Core Informatics, provider of cloud-based platforms supporting scientific data management.[40] In August, the company acquired Patheon, a contract development and manufacturing organization serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion.[41] As of 2017, the company had revenues of $20.9 billion, and was a Fortune 500 company.[42]

In September 2018, Thermo Fisher Scientific announced it had signed a definitive agreement with Becton, Dickinson and Company (BDX) to acquire their Advanced Bioprocessing business. This BD business had annualized revenue of approximately $100 million; as of October 16, 2018, it had been integrated into Thermo Fisher's Life Sciences Solutions Segment.[43]

In March 2019, Thermo Fisher Scientific announced its entry into the gene therapy manufacturing market with a $1.7 billion cash acquisition for Brammer Bio.[44][45][46] In May 2019, Thermo Fisher Scientific partnered with MMJ International Holdings to manufacture drug products developed by MMJ for the treatment of multiple sclerosis and Huntington's disease.[47] In June, the business announced it would acquire mass spectrometry software provider, HighChem.[48]

In March 2020, Thermo Fisher Scientific received emergency use authorization from the FDA for a test for SARS-CoV-2 to help mitigate the COVID-19 pandemic. Thermo Fisher also partnered with its biopharma customers, including Pfizer and Moderna, to support the development and production of new mRNA-based COVID-19 vaccines.[49][50]

In March 2020, Thermo Fisher Scientific agreed to purchase Qiagen, a molecular diagnostics company, for $10.1 billion.[51] In July, the offer for Qiagen was raised from €39 to €43 per share (€11.3 billion in total).[52][53] On August 13, the company announced that its offer to acquire all of the ordinary share had lapsed, and it terminated the acquisition agreement.[54]

In August 2020, Thermo Fisher Scientific opened its new Lenexa facility aimed at boosting the production and manufacturing of COVID-19 testing supplies.[55] In December the business announced it would acquire Phitonex, Inc.[56]

In January 2021, Thermo Fisher Scientific announced it had acquired Belgium-based viral vector manufacturer, Henogen SA, from Groupe Novasep SAS for €725 million in cash[57][58][59] and point-of-care molecular diagnostics provider Mesa Biotech, Inc. for up to $550 million.[60][61]

In April 2021, Thermo Fisher Scientific announced the acquisition of PPD, Inc., a contract research organization, for a total cash purchase price of $17.4 billion-plus the assumption of approximately $3.5 billion of net debt. PPD generated $4.7 billion in revenue during FY 2020, and this transaction, which values their company at approximately $20.9 billion.[62] In November, the business announced it would acquire PharmaFluidics and its μPAC range of micro-chip-based chromatography products.[63]

In January 2022, Thermo Fisher Scientific acquired PeproTech, a developer and manufacturer of recombinant proteins, for $1.85 billion. PeproTech became part of Thermo Fisher’s biosciences business and was integrated into the Life Sciences Solutions Segment.[64]

In October 2022, the company agreed to buy British diagnostics firm, The Binding Site Group, in an all-cash deal for US$2.6billion from Nordic Capital.[65][66] The acquisition completed in January 2023.[67]

In July 2023, the business announced it would acquire CorEvitas, LLC from Audax Private Equity for more than $900 million in cash.[68] In August 2023, it was announced Thermo Fisher had completed the acquisition for $912.5 million (in cash).[69]

In October 2023, Thermo Fisher Scientific acquired Olink Holding for $3.1 billion.[70]

In February 2025, Thermo Fisher announced the acquisition of Solventum’s purification and filtration business for $4.1 billion.[71]

In July 2025, Thermo Fisher added drug manufacturing capabilities in the United States through its purchase of a sterile fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey.[72]

In October 2025, Thermo Fisher announced a deal to acquire Clario Holdings—an endpoint data management solutions provider—for $8.88 billion in cash from a shareholder group including Novo Holding. The transaction was expected to close mid-2026.[73]

  • Thermo Fisher Scientific (formed in 2006 by the merger of Thermo Electron and Fisher Scientific)
  • Thermo Fisher Scientific
  • Fisher Scientific
  • Scientific Materials Co. (Est 1902)
  • Scientific Supplies, Ltd (Acq 1925)
  • Eimer & Amend (Acq 1940)
  • E. Machlett & Sons (Acq 1957)
  • Janssen Chimica
  • Eastman Kodak Company (Organic Chemicals division)
  • Apogent Technologies Inc. (Acq 2004)
  • Athena Diagnostics (Acq 2006)
  • Thermo Electron
  • Kendro Laboratory Products (Acq 2005)
  • Rupprecht and Patashnick Co., Inc. (Acq 2005)
  • NITON LLC (Acq 2005)
  • InnaPhase Corporation (Acq 2004)
  • US Counseling Services, Inc. (Acq 2004)
  • Jouan SA (Acq 2004)
  • Laboratory Management Systems, Inc. (Acq 2003)
  • Phadia (Acq 2011)
  • Life Technologies (Acq 2013)
  • Invitrogen Corporation (Merged 2008)
  • NOVEX
  • Research Genetics, Inc (Acq 1999)
  • Ethrog Biotechnology
  • Molecular Probes
  • Dynal
  • Panvera
  • InforMax
  • BioSource
  • CellzDirect
  • Zymed
  • Caltag Laboratories
  • Applied Biosystems (Merged 2008)
  • Advanced Scientifics (Acq 2015)
  • Alfa Aesar (Acq 2015)
  • Affymetrix (Acq 2016)
  • Genetic MicroSystems (Acq 1999)
  • Neomorphic (Acq 2000)
  • ParAllele Bioscience
  • USB Corporation (Acq 2008)
  • Panomics (Acq 2008)
  • True Materials (Acq 2000)
  • eBioscience (Acq 2012)
  • Compendia Bioscience (Acq 2012)
  • FEI Company (Acq 2016) [74]
  • FEI Company (Merged 1997)
  • Field Electron and Ion Co. (Est 1971)
  • Philips Electron Optics
  • Micrion (Acq 1999)
  • MTI-GlobalStem (Acq 2016)
  • Finesse Solutions, Inc. (Acq 2017) [75]
  • Core Informatics (Acq 2017)
  • Patheon (Acq 2017)
  • Agere Pharmaceuticals (Acq 2015)
  • Gallus Pharmaceuticals (Acq 2014)
  • Royal DSM NV (Pharmaceutical div, merged 2014)
  • MOVA (Acq 2004)
  • Banner Pharmacaps (Acq 2013)
  • Brammer Bio (Acq 2019) [76]
  • Phitonex, Inc. (Acq 2020)
  • Henogen S.A. (Acq 2021) [77]
  • Mesa Biotech, Inc. (Acq 2021) [78]
  • PPD, Inc. (Acq 2021) [79]
  • Acurian (Acq 2013)
  • Evidera (Acq 2016)
  • Medimix (Acq 2019)
  • PharmaFluidics (Acq 2021)
  • PeproTech (Acq 2021) [80]
  • The Binding Site Group (Acq 2023)
  • CorEvitas, LLC (Acq 2023)
  • Olink Holding (Acq 2023)

Leadership

Marc N. Casper is chairman, president and chief executive officer of Thermo Fisher Scientific.[81] He first joined Thermo Electron in December 2001 as Vice President of the Life and Laboratory Sciences segment. In November 2006, when Thermo Electron and Fisher Scientific merged to form Thermo Fisher Scientific, Casper was named executive vice president of the company and president of the Analytical Technologies Group. He became president and CEO in 2009.[82]

Partnerships

In September 2017, Thermo Fisher Scientific signed an agreement with the Institute of Pathology Heidelberg (IPH) to establish its Center of Molecular Pathology at Heidelberg University Hospital as the newest member of the Next Generation Sequencing Companion Dx Center of Excellence Program (COEP). The initiative focuses on establishing strategic collaborations with leading, European-based organizations that can lead studies using Thermo Fisher's Oncomine portfolio of research panels destined for development as companion diagnostics to help drive precision oncology in the region.[83]

In 2021, Thermo Fisher announced the construction of a cell therapy development, manufacturing and collaboration center in cooperation with University of California, San Francisco on the school's Mission Bay campus.[84]

In February 2022, Thermo Fisher Scientific announced a 15-year strategic collaboration agreement with Moderna, Inc. The collaboration was designed to scale up the manufacturing of Moderna’s COVID-19 vaccine and other investigational mRNA products.[85]

In May 2023, Thermo Fisher partnered with Pfizer, with plans to work together on expanding testing capabilities for lung and breast cancer patients.[86]

In November 2023, Thermo Fisher partnered with Flagship Pioneering, a biotechnology company.[87] Together, they plan to create companies in the biotechnology field.[88]

In January 2025, Thermo Fisher partnered with the UK Biobank Pharma Proteomics Project (UKB-PPP) to support the world’s largest human proteomics study. Using the Olink Explore platform, UKB-PPP seeks to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose, and treat diseases.[89][90]

In February 2025, Thermo Fisher entered a 10-year virtual power purchase agreement (VPPA) with X-ELIO to secure 118 megawatts of solar energy, moving its European operations closer to a 100% renewable electricity goal.[91]

In June 2025, Thermo Fisher partnered with the Regeneron Genetics Center which selected the Olink Explore platform for large-scale proteomics investigation involving nearly 200,000 patient samples aiming to unlock new insights into the dynamic biology and mechanisms of human disease.[92]

Controversies

Xinjiang and Tibet

In February 2019, Thermo Fisher Scientific announced that it would stop selling its equipment in Xinjiang.[93] In June 2020, Thermo Fisher Scientific was reported to sell its equipment to security services in China for use in what was alleged as part of a genetic surveillance program.[94] A report from the Australian Strategic Policy Institute found that Thermo Fisher Scientific collaborated with the Chinese Ministry of Public Security to develop a Huaxia PCR amplification kit specifically to identify the genotypes of Uyghur, Tibetan and Hui ethnic minorities.[95] In June 2021, The New York Times reported that, despite bans, Thermo Fisher Scientific equipment continued to be sold to police in Xinjiang.[96]

In 2022, following reports that Thermo Fisher Scientific had sold products to police in the Tibet Autonomous Region,[97] the Inter-Parliamentary Alliance on China called on governments to "investigate and suspend commercial activities with companies providing the PRC government with technologies to carry out biometric surveillance in the Uyghur Region, Tibet and elsewhere in the PRC, including the PRC state backed BGI Group and US firm Thermo Fisher."[98] Thermo Fisher Scientific subsequently halted sales of DNA collection kits in Tibet.[99]

HeLa cells

In October 2021 the estate of Henrietta Lacks sued to get past and future payment for the alleged and widely known unauthorized sale by Thermo Fisher Scientific of her HeLa cells which are essential in many types of research.[100] Over 50 million tons of her cells have been produced and used in over 60,000 scientific studies touching virtually every realm of medicine, including the development of polio vaccines, gene mapping, in-vitro fertilization, and multitudes more.[101][102][103]

In May 2022, it was announced Thermo Fisher Scientific went to court to seek a dismissal of the lawsuit.[104] In late July 2023, with the motion to dismiss still outstanding, the court ordered the parties to attend a settlement conference.[105][106] Soon after that, settlement of the suit, with undisclosed terms, was announced.[107]

Mexican plant

In 2013, Opengate Capital Group LLC filed suit against Thermo Fisher Scientific for selling it a manufacturing plant controlled by the Gulf Cartel. According to Opengate Capital, the company withheld important documents and pressured employees into concealing the presence of the drug cartel.[108][109]

External links

References

  1. Thermo Fisher Scientific Inc. 2025 Annual Report (Form 10-K) U.S. Securities and Exchange Commission, February 26, 2026^
  2. David Gelles. Thermo bid wins Life Technologies auction Financial Times, 15 April 2013, retrieved 29 November 2021^
  3. Don Seiffert. Thermo Fisher to buy 480-employee chemical maker based in Haverhill bizjournals.com, Boston Business Journal, retrieved 29 November 2021^
  4. Thermo Fisher Scientific to Acquire Affymetrix for $1.3B genengnews.com, Genetic Engineering & Biotechnology News, 11 January 2016, retrieved 29 November 2021^
  5. Leslie Picker. Thermo Fisher to Acquire FEI for $4.2 billion The New York Times, 27 May 2016, retrieved 29 November 2021^
  6. GEN Staff Writer. Thermo Fisher Acquiring BD's Advanced Bioprocessing Business GEN - Genetic Engineering and Biotechnology News, 2018-09-07, retrieved 2022-08-09^
  7. Thermo Fisher Scientific Completes Acquisition of PPD, Inc. ir.thermofisher.com, retrieved 2022-08-09^
  8. Fortune 500 Fortune, retrieved 2025-08-21^
  9. George Hatsopoulos, senior lecturer emeritus and MIT Corporation life member emeritus, dies at 91 "Thermodynamics expert and longtime Department of Mechanical Engineering affiliate founded Thermo Electron, a world leader in instrumentation... ...along with Peter Nomikos, he co-founded the Thermo Electron Corporation" 21 September 2018 web.mit.edu^
  10. Financial Statements for Thermo Fisher Scientific Inc. - Google Finance google.com^
  11. Archived copy retrieved 2013-07-17^
  12. PPG Vice President Fisher Dies. thefreelibrary.com, retrieved July 17, 2013^
  13. Thermo Fisher Scientific : Corporate Profile^
  14. Bloomberg News. Deal by Lab Equipment Makers Priced at $10.6 Billion in Stock The New York Times, 2006-05-09, retrieved 2023-07-23^
  15. Merger of Thermo Electron and Fisher Scientific Completed, Forming Thermo Fisher Scientific, press release, November 9, 2006^
  16. Thermo Electron Corporation, In the Matter of Federal Trade Commission, 2006-10-17, retrieved 2024-01-25^
  17. 3 April 2007. Riverlake Partners, LLC Acquires UK-based Genevac, Ltd. Press Release.^
  18. FTC Approves Proposed Divestiture in Matter of Thermo Electron Corporation Federal Trade Commission, 2007-03-30, retrieved 2024-01-25^
  19. COMPANY NEWS; Thermo Unit Sets Deal for Finnigan The New York Times, 25 April 1990, retrieved 25 May 2024^
  20. Fisher Scientific buying Perbio Science for $714M www.bizjournals.com, 26 June 2003, retrieved 25 May 2024^
  21. Thermo Scientific - US www.thermofisher.com, retrieved 2021-02-04^
  22. Life Technologies BioImage, retrieved 2017-04-24^
  23. BioImage Company Profile: Acquisition & Investors PitchBook, retrieved 2021-02-04^
  24. Life Technologies BioImage, retrieved 2017-04-24^
  25. Thermo Fisher to buy Dionex for $2.1 billion Reuters, 2010-12-13, retrieved 2022-06-01^
  26. Thermo Fisher Rises to Record After $3.5 Billion Phadia Buy Bloomberg^
  27. Zachary Brennan. Price of Life Tech Steady at $11B as Roche Joins Bidding War Outsourcing-Pharma.com, March 2013, retrieved 2017-08-03^
  28. Bill Berkrot and Susan Kelly. Thermo Fisher to buy Life Tech for $13.6 billion Reuters, 15 April 2013^
  29. Applied Biosystems, Invitrogen complete $6.7 billion merger www.bizjournals.com, 21 November 2008, retrieved 27 May 2024^
  30. G. E. N. Staff. Thermo Fisher Acquiring BD's Advanced Bioprocessing Business GEN - Genetic Engineering and Biotechnology News, 7 September 2018, retrieved 27 May 2024^
  31. Thermo Fisher Scientific Acquires Single-Use Specialist ASI for $300 Million - GEN News Highlights - GEN GEN, 5 February 2015^
  32. Thermo Fisher Scientific Agrees to Acquire Research Chemicals Firm GEN, 25 June 2015^
  33. Thermo Fisher Scientific - Thermo Fisher Scientific Completes Acquisition of Alfa Aesar to Significantly Expand Laboratory Chemicals Offering retrieved 5 January 2016^
  34. GEN Staff Writer. Thermo Fisher Scientific to Acquire Affymetrix for $1.3B January 11, 2016^
  35. Kristen Hallam. Thermo Fisher Scientific to Buy FEI for About $4.2 Billion Bloomberg, 27 May 2016, retrieved 2016-05-28^
  36. Don Seiffert. Thermo CEO mum on whether he had competitors in $4.2B bid for FEI Boston Business Journal, 27 May 2016, retrieved 31 May 2016^
  37. Thermo Fisher Scientific Acquires MTI-GlobalStem - Thermo Fisher Scientific eNews news.thermofisher.com, retrieved April 4, 2017^
  38. Thermo Fisher Scientific Receives Early Termination of Hart-Scott-Rodino Waiting Period for Acquisition of Finesse Solutions, Inc. - Thermo Fisher Scientific eNews news.thermofisher.com, retrieved April 4, 2017^
  39. Thermo Fisher Scientific Completes Acquisition of Finesse Solutions, Inc. - Thermo Fisher Scientific eNews news.thermofisher.com, retrieved April 4, 2017^
  40. Thermo Fisher Scientific Acquires Core Informatics, Provider of Leading Cloud-Based Scientific Data Platforms - Thermo Fisher Scientific eNews news.thermofisher.com, retrieved April 4, 2017^
  41. Pharmaceutical Technology Editorial Staff. Thermo Fisher Scientific Acquires Patheon www.pharmtech.com, retrieved 2017-09-12^
  42. Fortune 500 Companies 2018: Who Made the List Fortune, retrieved 2018-11-19^
  43. Thermo Fisher Scientific. Thermo Fisher To Acquire BD's Advanced Bioprocessing Business - Quick Facts markets.businessinsider.com, retrieved 2022-08-22^
  44. Jonathan Saltzman- Reporter. Thermo Fisher gets into gene therapy with $1.7b deal for Brammer Bio - The Boston Globe BostonGlobe.com, retrieved 2019-03-27^
  45. Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing MediaRoom, retrieved 2019-03-27^
  46. Thermo Fisher shoulders into gene therapy manufacturing with $1.7B deal for Brammer Fierce Pharma, 25 March 2019, retrieved 2019-03-27^
  47. Joana Carvalho Phd. To Support MS Cannabinoid Studies, MMJ Asks US Agency to OK Shipments from Canada Multiple Sclerosis News Today, 2019-08-14, retrieved 2020-01-06^
  48. Thermo Fisher Scientific Acquires HighChem, Provider of Mass Spectrometry Software BioSpace, retrieved 2020-06-20^
  49. Moderna partners with Thermo Fisher to scale up Covid vaccine production CNBC, 1 June 2021, retrieved 25 May 2024^
  50. Agnieszka Flak. Thermo Fisher to work with Pfizer-BioNtech on vaccine production in Italy March 25, 2021, retrieved 25 May 2024^
  51. Carlo Martuscelli. Thermo Fisher to Buy Diagnostic Company for $10.1 Billion Wall Street Journal, 2020-03-03, retrieved 2020-03-03^
  52. Thermo Fisher's sweetened Qiagen bid fails to win over key investor Reuters, July 16, 2020^
  53. Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement BioSpace^
  54. Thermo Fisher Scientific. Thermo Fisher Scientific Announces Results of Offer to Acquire QIAGEN, Lapse of Offer and Termination of Acquisition Agreement www.prnewswire.com^
  55. Biotech firm Thermo Fisher Scientific opens Lenexa facility aimed at boosting Kansas' COVID-19 testing capacity Shawnee Mission Post - Community news and events for northeast Johnson County, 2020-08-28, retrieved 2020-09-10^
  56. Thermo Fisher Scientific Acquires Programmable Dye Platform Pioneer Phitonex BioSpace^
  57. Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep BioSpace^
  58. Thermo Fisher Takes Deep Dive into Cell and Gene Therapy with Viral Vector Business Buy BioSpace, January 15, 2021^
  59. Fraiser Kansteiner. Thermo Fisher links up with UCSF on soup-to-nuts cell therapy factory and research center Fierce Pharma, 2021-05-21, retrieved 2023-09-27^
  60. Thermo Fisher Scientific to Acquire Point-of-Care Molecular Diagnostics Provider Mesa Biotech BioSpace, 19 January 2021, retrieved 27 May 2024^
  61. Amruta Khandekar. Thermo Fisher buys Henogen for nearly $880 million in gene therapy expansion 15 January 2021, retrieved 27 May 2024^
  62. Thermo Fisher expands pharma service business with $17.4 bln PPD acquisition Reuters, 2021-04-15^
  63. Thermo Fisher Scientific Adds Patterned Microchip-based Technology to Liquid Chromatography Portfolio November 2021^
  64. Thermo Fisher Scientific acquires PeproTech for $1.85bn Medical Device Network, 6 January 2022, retrieved 27 May 2024^
  65. Leroy Leo, Pratik Jain. Thermo Fisher to buy diagnostics firm Binding Site for $2.6 bln Reuters, 2022-10-31^
  66. Jan-Henrik Foerster, Michelle F Davis. Thermo Fisher to buy UK's Binding Site in $2.6 billion deal Bloomberg News, 2022-10-30^
  67. Thermo Fisher completes $2.8bn acquisition of The Binding Site Group NS Medical Devices, 2023-01-03, retrieved 2023-01-03^
  68. Thermo Fisher Scientific to Acquire CorEvitas July 6, 2023^
  69. Akosua Mireku. Thermo Fisher completes $912.5m acquisition of CorEvitas Pharmaceutical Technology, 2023-08-15, retrieved 2023-08-15^
  70. Thermo Fisher Scientific to buy Olink in $3.1 billion deal Reuters, 2023-10-17, retrieved 2023-10-23^
  71. Angus Liu. Thermo Fisher buys 3M spinoff's filtration unit for $4.1B www.fiercepharma.com, 2025-02-25, retrieved 2025-08-21^
  72. Kevin Dunleavy. Thermo Fisher buys fill-finish plant in New Jersey from Sanofi www.fiercepharma.com, 2025-07-16, retrieved 2025-08-21^
  73. Adriano Marchese. Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 Billion The Wall Street Journal, 2025-10-29, retrieved 2025-10-29^
  74. Thermo Fisher Scientific Completes Acquisition of FEI Company^
  75. Thermo Fisher Scientific Completes Acquisition of Finesse Solutions, Inc.^
  76. Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing^
  77. Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep^
  78. Thermo Fisher Scientific Completes Acquisition of Mesa Biotech^
  79. Thermo Fisher Scientific Completes Acquisition of PPD, Inc.^
  80. Thermo Fisher Scientific Completes Acquisition of PeproTech, a Leader in Recombinant Proteins^
  81. CEO of the Week: Thermo Fisher Scientific's Marc N. Casper Chief Executive, June 21, 2020^
  82. This Top CEO's Rock-Solid Company Acts Like A Teenager Investor's Business Daily, 23 December 2020, retrieved 27 May 2024^
  83. Institute of Pathology Joins Thermo Fisher Scientific to Drive Oncology Companion Diagnostic Development Technology Networks, retrieved 2017-09-12^
  84. Fraiser Kansteiner. Drugs from J&J, Merck, Novartis, BMS and more set for first round of Medicare price negotiations: CMS 2023-08-29, retrieved 2023-08-31^
  85. Fraiser Kansteiner. MANUFACTURING Moderna taps Thermo Fisher for 15-year mRNA production pact for COVID vaccines and more Feb 23, 2022, retrieved 25 May 2024^
  86. Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing Yahoo Finance, 2023-05-10, retrieved 2024-01-30^
  87. Conor Hale. Thermo Fisher teams up with Flagship Pioneering to forge new life science tool startups Fierce Biotech, 28 November 2023, retrieved 30 January 2024^
  88. Kiays Khalil. Thermo Fisher and Flagship Pioneering partner to establish platform companies Medical Device Network, 2023-11-30, retrieved 2024-01-30^
  89. Research & Development. Thermo Fisher Scientific’s Olink platform selected for world’s largest human proteome study manufacturingchemist.com, retrieved 2025-08-21^
  90. Unlocking the Human Proteome Proteomics & Metabolomics from Technology Networks, retrieved 2025-08-21^
  91. Rhiannon Temporal. Thermo Fisher Scientific announces 10-year VPPA with X-ELIO European Pharmaceutical Manufacturer, 2025-02-05, retrieved 2025-08-21^
  92. Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples Proteomics & Metabolomics from Technology Networks, retrieved 2025-08-21^
  93. Sui-Lee Wee. China Uses DNA to Track Its People, With the Help of American Expertise The New York Times, 2019-02-21, retrieved 2020-06-20^
  94. Sui-Lee Wee. China Is Collecting DNA From Tens of Millions of Men and Boys, Using U.S. Equipment The New York Times, 2020-06-17, retrieved 2020-06-17^
  95. Emile Dirks, James Leibold. Genomic surveillance www.aspi.org.au, June 16, 2020, retrieved 2020-10-04^
  96. Sui-Lee Wee. China Still Buys American DNA Equipment for Xinjiang Despite Blocks The New York Times, 2021-06-11, retrieved 2021-06-30^
  97. Mara Hvistendahl. Tibetan Police Bought Thermo Fisher DNA Equipment, Chinese Government Documents Show The Intercept, September 13, 2022, retrieved 2023-03-19^
  98. Andrew Operations. Legislators call for sanctions on firms complicit in mass DNA harvesting of Tibetans and Uyghurs Inter-Parliamentary Alliance on China, 2022-12-16, retrieved 2023-03-19^
  99. Bethany Allen-Ebrahimian. Thermo Fisher halts DNA collection kit sales in Tibet Axios, January 3, 2024, retrieved January 3, 2024^
  100. Estate of Henrietta Lacks sues Thermo Fisher Scientific over the improper sale of her immortal cells^
  101. Henrietta Lacks' 'Immortal' Cells^
  102. Henrietta Lacks' Descendants Sue Company They Believe Profits From Her Immortal Cells IFLScience, 6 October 2021^
  103. Henrietta Lacks' estate sues drug company that sold her cells TheGuardian.com, 4 October 2021^
  104. Thermo Fisher seeks dismissal of Henrietta Lacks' family's lawsuit regarding sale of her cells News, 2022-05-17, retrieved 2022-06-16^
  105. Henrietta Lacks family lawsuit against biotech company ordered to go to settlement conference next week Baltimore Sun, 28 July 2023^
  106. Family of Henrietta Lacks asks court to reject Thermo Fisher's second motion to dismiss lawsuit Baltimore Sun, 22 February 2023^
  107. Amanda Holpuch. Family of Henrietta Lacks Settles With Biotech Company That Used Her Cells The New York Times, 1 August 2023^
  108. Joseph Walker. Thermo Sold Plant Overrun by Drug Cartel, Suit Alleges Wall Street Journal, 2013-05-11, retrieved 2022-02-05^
  109. Thermo Fisher sued over sale of Mexico plant used by drug cartel Reuters, 2013-05-11, retrieved 2022-02-05^